Aradigm's ARD-3150 meets bronchiectasis endpoint

Aradigm Corp. (OTCBB:ARDM) said top-line data from the Phase IIb ORBIT-2 trial to treat non-cystic fibrosis (CF) bronchiectasis showed that once-daily inhaled ARD-3150 met the primary endpoint of sign...